Topical Tofacitinib for the Treatment of Alopecia Areata and Its Variants

Completed · Phase 2

Conditions studied: Alopecia Areata, Alopecia Totalis, Alopecia Universalis

In brief

The purpose of the study is to investigate the use of topical tofacitinib to promote hair regrowth in patients with alopecia areata, alopecia totalis, and alopecia universalis.

Key facts

Study ID

NCT02812342

Run by

Yale University

People needed

10

Starts

2016-09-01

Expected to finish

2018-12-01

Last updated by the study team

2019-01-30

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of AA with at least 2 patches of alopecia involving the scalp, AT or AU
• Stable hair loss present for 6 months or longer
• No treatment for alopecia areata in the past 1 month
• No evidence of spontaneous hair regrowth

You may not qualify if…

• Patients have received treatment known to affect alopecia areata within 1 month of enrolling in the study
• Patients whose current episode of AT or AU is more than 5 years
• Patients with a history of malignancy (except history of successfully treated basal cell or squamous cell carcinoma of the skin)
• Patients known to be HIV or hepatitis B or C positive
• Patients with positive tuberculin skin test or positive QuantiFERON® TB test
• Patients with leukopenia or anemia
• Patients with renal or hepatic impairment
• Patients taking immunosuppressive medications, including but not limited to prednisone, methotrexate, mycophenolate mofetil, azathioprine, tacrolimus, cyclosporine, or TNF-α inhibitors
• Women who are pregnant or nursing

Where it is running

• Yale-New Haven Hospital — New Haven, Connecticut, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.